Caladrius in-licenses refractory angina asset from Shire

6 March 2018
2019_biotech_test_vial_discovery_big

USA-based Caladrius Biosciences (Nasdaq: CLBS) has acquired an exclusive worldwide license to data from a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina.

The CD34+ cell therapy program was an asset gained through the Baxalta acquisition by Shire (LSE: SHP) in 2016, though the Ireland-incorporated drugmaker is offloading it as part of its efforts to out-license non-strategic assets to sharpen the company focus on rare diseases.

"We believe that the growing body of clinical data in support of CD34+ cell therapy as a treatment for refractory angina is very encouraging"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology